Enrollment

REBETOL®
(ribavirin)
CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
MAXALT®
(rizatriptan benzoate)
SINGULAIR®
(montelukast sodium)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 

Gardasil Pregnancy Registry

Please note that the Pregnancy Registry for Gardasil is now CLOSED to new enrollment.

The Pregnancy Registry for Gardasil has achieved its goal of conducting at least 5 years of enhanced surveillance of exposures to Gardasil during pregnancy. Therefore, new patient enrollment was discontinued on December 31, 2012. Follow-up of patients currently enrolled will continue until the last patient data is collected or it is determined that the patient is lost to follow-up.

Registry personnel wish to convey their gratitude to the women and health care providers who reported cases of vaccination during pregnancy and completed registry questionnaires. Their contributions allowed our ongoing surveillance of this product to monitor and describe its safety profile.

The Company continues to seek information on patient exposures to Gardasil during pregnancy and the pregnancy outcomes. For questions related to exposure to Gardasil during pregnancy or to report new cases of exposure to Gardasil during pregnancy, please contact Merck’s call center at 1-877-888-4231.

 


CRIXIVAN  |  GARDASIL  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  MAXALT  |  PROQUAD  |  REBETOL  |  SINGULAIR  |  VARIVAX  |  ZOSTAVAX  | 
Enrollment  |  Home  |  Privacy Policy

Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.